The objective of this study was to describe a “real-world” experience of mCSPC patients treated with apalutamide, enzalutamide, and abiraterone acetate, with a focus on PSA response and development of castration resistance outcomes.
This study identified patients with mCSPC newly initiated on apalutamide, enzalutamide, or abiraterone acetate using data from 77 community-based urology practices between September 2018 and April 2022.
-------------------------------------------------------
In this shootout:
apalutamide ranked 1st on all measures
enzalutamide ranked 2nd on all measures
abiraterone ranked 3rd on all measures
-------------------------------------------------------
How much should I care?
1. This is doublet therapy so does not include triplet therapy which is another emerging effective option.
2. You can find other shootouts where the rankings are rearranged.
3. Consult with your MO for your best treatment selection based on your unique circumstances.
-------------------------------------------------------
Also the newer AR targeted agent, Darolutamide, is not included since it has not been approved for doublet therapy in mCSPCa (triplet only) yet. Doublet approval for Darolutamide will be coming soonish, due to 2 new phase 3 RCT's.
See more about these new trials here:
ARASEC Trial, watch video here:
urotoday.com/trials-in-prog...
ARANOTE Trial, watch video here: